COMPANY

R&D

Gene Therapy of GenixCure

a gene therapy that targets degenerative neurological/rare diseases, etc

  • Optimizing Codon/promoter to increase efficiency

    01

  • Adoption of our self-developed AAV vector that is
    delivered specifically to cells/tissues

    02

  • Process & analytical development through our
    in-house process development lab

    03
CARE™, Cell-specific AAV Research Engine

The key to gene therapy is the safe arrival of the gene into the target tissue
CARE™ will meet the tissue-specific demand for AAV capsid, which is required by the growth of the gene therapy tax market.

  • Directed evolution: Secured a Capsid library with
    a diversity of about 10¹²

    01

  • Rational design : InsightMiner™

    02

  • Based on SOP, secured the technology for
    producing an AAV library

    03

  • Secured over 60 vector candidates
    including XOB-031

    04